5 min listen
AAV & Lentivirus Gene Therapies with Sio Gene Therapeutics' Dr. Pavan Cheruvu
AAV & Lentivirus Gene Therapies with Sio Gene Therapeutics' Dr. Pavan Cheruvu
ratings:
Length:
57 minutes
Released:
May 24, 2021
Format:
Podcast episode
Description
Fresh on the heels of a significant data readout on its AXO-AAV-GM1 candidate at the recent ASGCT meeting, Sio Gene Therapies CEO Pavan Cheruvu, M.D. joins the Business of Biotech podcast. We discuss Dr. Cheruvu's formative years and inspiration, his company's origins, its progress developing AAV and lentiviral gene therapies to treat GM1 gangliosidosis, Tay-Sachs / Sandhoff disease, and Parkinson's disease, and the challenges the company has overcome in a hybrid manufacturing environment that will ultimately transfer entirely in-house.
Released:
May 24, 2021
Format:
Podcast episode
Titles in the series (100)
Business Of Biotech Trailer by Business Of Biotech